^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    STAMP inhibitor

    Related drugs:
    1d
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Apr 2026 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    7d
    PONTHIAC: Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib (2025-521126-15-00)
    P1/2, N=30, Not yet recruiting, Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    12d
    Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML (clinicaltrials.gov)
    P3, N=8, Terminated, Sarit Assouline | N=164 --> 8 | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; Insufficient patient accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Scemblix (asciminib)
    14d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=14, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    19d
    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • idarubicin hydrochloride • Scemblix (asciminib) • fludarabine IV • Neupogen (filgrastim)
    21d
    CABL001I12202: Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. (2025-522138-29-00)
    P1/2, N=7, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    22d
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2035 --> Jun 2036 | Trial primary completion date: Jan 2033 --> Jul 2033
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    27d
    ASC2ADHERE: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany (clinicaltrials.gov)
    P=N/A, N=380, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Scemblix (asciminib)
    28d
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    1m
    ASCENdANT: Asciminib in HER2+ Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Feb 2026 --> Jul 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Scemblix (asciminib)
    1m
    CABL001L12101: Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL (2025-522019-40-00)
    P1/2, N=14, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I
    |
    cytarabine • vincristine • Scemblix (asciminib)
    2ms
    Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence. (PubMed, Hematol Rep)
    Its greatest clinical value appears to lie in rational combination regimens, maintenance strategies, and bridging to definitive therapies rather than single-agent salvage. Emerging structural biomarkers and ongoing clinical trials are expected to further refine patient selection, sequencing, and optimal integration of asciminib, particularly in CNS-involved disease and post-CAR-T cell relapse.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 T315I
    |
    Scemblix (asciminib)